Assembly Biosciences, Inc. (ASMB)
USD 8.78
(-5.69%)
USD 8.78
(-5.69%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -17.49 Million USD | 64.25% |
| 2022 | -48.95 Million USD | -25.04% |
| 2021 | -39.15 Million USD | 20.61% |
| 2020 | -49.31 Million USD | -43.09% |
| 2019 | -34.46 Million USD | 16.9% |
| 2018 | -41.47 Million USD | 49.45% |
| 2017 | -82.03 Million USD | -187.08% |
| 2016 | -28.57 Million USD | -5.41% |
| 2015 | -27.1 Million USD | 6.82% |
| 2014 | -29.09 Million USD | -7.5% |
| 2013 | -27.06 Million USD | -32.08% |
| 2012 | -20.48 Million USD | 44.59% |
| 2011 | -36.97 Million USD | -206.06% |
| 2010 | -12.08 Million USD | -235.27% |
| 2009 | 8.93 Million USD | 54.8% |
| 2008 | 5.76 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -17.46 Million USD | -3.86% |
| 2024 Q1 | -16.81 Million USD | 3.92% |
| 2023 Q3 | -25.73 Million USD | -29.61% |
| 2023 Q4 | -17.49 Million USD | 32.01% |
| 2023 FY | -17.49 Million USD | 64.25% |
| 2023 Q1 | -40.85 Million USD | 16.54% |
| 2023 Q2 | -19.85 Million USD | 51.4% |
| 2022 Q1 | -45.47 Million USD | -16.14% |
| 2022 Q3 | -50.38 Million USD | -32.66% |
| 2022 Q4 | -48.95 Million USD | 2.84% |
| 2022 Q2 | -37.97 Million USD | 16.47% |
| 2022 FY | -48.95 Million USD | -25.04% |
| 2021 Q3 | -63.52 Million USD | -23.22% |
| 2021 Q1 | -69.67 Million USD | -41.29% |
| 2021 Q2 | -51.55 Million USD | 26.01% |
| 2021 Q4 | -39.15 Million USD | 38.37% |
| 2021 FY | -39.15 Million USD | 20.61% |
| 2020 FY | -49.31 Million USD | -43.09% |
| 2020 Q2 | -85.57 Million USD | -180.36% |
| 2020 Q3 | -47.53 Million USD | 44.45% |
| 2020 Q4 | -49.31 Million USD | -3.74% |
| 2020 Q1 | -30.52 Million USD | 11.44% |
| 2019 Q1 | -15.88 Million USD | 61.7% |
| 2019 Q4 | -34.46 Million USD | -191.57% |
| 2019 FY | -34.46 Million USD | 16.9% |
| 2019 Q3 | -11.82 Million USD | 44.69% |
| 2019 Q2 | -21.36 Million USD | -34.55% |
| 2018 FY | -41.47 Million USD | 49.45% |
| 2018 Q2 | -54.19 Million USD | 19.03% |
| 2018 Q4 | -41.47 Million USD | 65.37% |
| 2018 Q3 | -119.75 Million USD | -120.98% |
| 2018 Q1 | -66.92 Million USD | 18.42% |
| 2017 Q4 | -82.03 Million USD | -201.07% |
| 2017 FY | -82.03 Million USD | -187.08% |
| 2017 Q3 | -27.24 Million USD | 30.94% |
| 2017 Q2 | -39.45 Million USD | 44.29% |
| 2017 Q1 | -70.81 Million USD | -147.83% |
| 2016 Q1 | -20.39 Million USD | 24.76% |
| 2016 Q2 | -20.34 Million USD | 0.26% |
| 2016 FY | -28.57 Million USD | -5.41% |
| 2016 Q3 | -23.79 Million USD | -16.97% |
| 2016 Q4 | -28.57 Million USD | -20.09% |
| 2015 Q1 | -96.05 Million USD | -230.18% |
| 2015 FY | -27.1 Million USD | 6.82% |
| 2015 Q4 | -27.1 Million USD | 25.53% |
| 2015 Q3 | -36.4 Million USD | 31.98% |
| 2015 Q2 | -53.51 Million USD | 44.28% |
| 2014 Q3 | -17.93 Million USD | 15.87% |
| 2014 FY | -29.09 Million USD | -7.5% |
| 2014 Q2 | -21.31 Million USD | 9.82% |
| 2014 Q1 | -23.63 Million USD | 12.65% |
| 2014 Q4 | -29.09 Million USD | -62.22% |
| 2013 Q3 | -32.22 Million USD | 3.78% |
| 2013 Q4 | -27.06 Million USD | 16.02% |
| 2013 FY | -27.06 Million USD | -32.08% |
| 2013 Q1 | -36.87 Million USD | -79.97% |
| 2013 Q2 | -33.48 Million USD | 9.18% |
| 2012 Q2 | -28.84 Million USD | 7.15% |
| 2012 Q4 | -20.48 Million USD | 13.03% |
| 2012 Q1 | -31.06 Million USD | 15.98% |
| 2012 FY | -20.48 Million USD | 44.59% |
| 2012 Q3 | -23.56 Million USD | 18.32% |
| 2011 Q3 | -53.29 Million USD | -368.79% |
| 2011 FY | -36.97 Million USD | -206.06% |
| 2011 Q1 | 1295.17 Billion USD | 10720833.26% |
| 2011 Q2 | -11.36 Million USD | -100.0% |
| 2011 Q4 | -36.97 Million USD | 30.62% |
| 2010 Q1 | 10.32 Million USD | 15.63% |
| 2010 Q2 | 10.03 Million USD | -2.79% |
| 2010 FY | -12.08 Million USD | -235.27% |
| 2010 Q4 | -12.08 Million USD | -243.8% |
| 2010 Q3 | 8.4 Million USD | -16.31% |
| 2009 Q4 | 8.93 Million USD | 0.0% |
| 2009 FY | 8.93 Million USD | 54.8% |
| 2008 FY | 5.76 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 68.718% |
| Alkermes plc | -166.73 Million USD | 89.505% |
| Agenus Inc. | 274.13 Million USD | 106.383% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 100.936% |
| Aptorum Group Limited | 1.35 Million USD | 1389.492% |
| Ardelyx, Inc. | 34.51 Million USD | 150.704% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 508.855% |
| Bicycle Therapeutics plc | -481.46 Million USD | 96.365% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 148.389% |
| ChromaDex Corporation | -24.04 Million USD | 27.233% |
| Chimerix, Inc. | -25.51 Million USD | 31.422% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 351.131% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 26.093% |
| CRISPR Therapeutics AG | -150.84 Million USD | 88.399% |
| Precision BioSciences, Inc. | -85.41 Million USD | 79.512% |
| Dyadic International, Inc. | -6.37 Million USD | -174.361% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | -9.829% |
| Fortress Biotech, Inc. | 7.66 Million USD | 328.297% |
| Lantern Pharma Inc. | -21.7 Million USD | 19.372% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 84.169% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -104.83% |
| Incyte Corporation | -3.17 Billion USD | 99.449% |
| IO Biotech, Inc. | -140.69 Million USD | 87.563% |
| Jaguar Health, Inc. | 29.39 Million USD | 159.539% |
| Novavax, Inc. | -298.29 Million USD | 94.134% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 427.881% |
| Opthea Limited | 28.15 Million USD | 162.147% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | -4.229% |
| ContextLogic Inc. | -232 Million USD | 92.457% |
| MiMedx Group, Inc. | -33.9 Million USD | 48.382% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 271.643% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -655.235% |
| NextCure, Inc. | -6.47 Million USD | -170.171% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 65.349% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -174.322% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 243.868% |
| Vaxcyte, Inc. | -368.22 Million USD | 95.248% |
| PDS Biotechnology Corporation | -32.7 Million USD | 46.501% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 201.279% |
| Pharming Group N.V. | 109.8 Million USD | 115.937% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | -0.592% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 90.014% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 5.512% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 5.512% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -146.465% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -198.618% |
| Acelyrin, Inc. | -216.9 Million USD | 91.932% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -211.91% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -915.023% |
| Summit Therapeutics Inc. | 34.67 Million USD | 150.467% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -157.225% |
| Senti Biosciences, Inc. | 1.74 Million USD | 1105.69% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 90.521% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 77.406% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -188.667% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 17639.516% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 2886.465% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 85.049% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 89.598% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 115.783% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -130.371% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 86.447% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 353.807% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 92.78% |
| Immix Biopharma, Inc. | -17.5 Million USD | 0.062% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 94.475% |
| MEI Pharma, Inc. | -3.7 Million USD | -372.308% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 239.869% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 110.819% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 162.962% |
| Fortress Biotech, Inc. | 7.66 Million USD | 328.297% |
| Precigen, Inc. | -481 Thousand USD | -3538.046% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 224.274% |
| AlloVir, Inc. | -62.69 Million USD | 72.087% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 68.535% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 128.377% |
| ImmuCell Corporation | 10.99 Million USD | 259.218% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 88.648% |
| Onconetix, Inc. | 5.33 Million USD | 428.223% |
| PureTech Health plc | -167.19 Million USD | 89.534% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 42.551% |
| Elevation Oncology, Inc. | -19.11 Million USD | 8.468% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -256.468% |
| Seer, Inc. | -4.24 Million USD | -312.712% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 27.2% |
| Innoviva, Inc. | 255.56 Million USD | 106.847% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 68.676% |
| ESSA Pharma Inc. | -33.62 Million USD | 47.953% |
| GlycoMimetics, Inc. | -40.98 Million USD | 57.303% |
| GT Biopharma, Inc. | -1.02 Million USD | -1613.908% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 74.184% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 128.567% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 86.949% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -26.292% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 39.391% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -23128.555% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 43.299% |
| Aptose Biosciences Inc. | -8.19 Million USD | -113.536% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -459.249% |
| Soligenix, Inc. | -4.95 Million USD | -253.401% |
| Century Therapeutics, Inc. | 847 Thousand USD | 2165.998% |
| Kura Oncology, Inc. | -20.11 Million USD | 13.018% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 57.242% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -108.371% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 1060.589% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -447.357% |
| Autolus Therapeutics plc | -186.59 Million USD | 90.622% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 64.508% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 93.655% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 151.065% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 110.646% |
| GRI Bio, Inc. | -1.79 Million USD | -875.418% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -94.8% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 47.383% |
| IGM Biosciences, Inc. | -72.6 Million USD | 75.899% |
| INmune Bio, Inc. | -25.41 Million USD | 31.136% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 111.593% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 65.457% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -7.69% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -506.567% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 146.032% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 57.511% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 154.882% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 104.63% |
| Verastem, Inc. | -37.27 Million USD | 53.058% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -92.869% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 66.259% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | -15.619% |
| Histogen Inc. | -7.48 Million USD | -133.725% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 19.012% |
| Surrozen, Inc. | -32.66 Million USD | 46.427% |
| Organovo Holdings, Inc. | -1.5 Million USD | -1061.181% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -316.297% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 192.293% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 768.922% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 521.054% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -108.79% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 59.719% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -20.046% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 94.476% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -2323.483% |
| Apollomics, Inc. | -27.39 Million USD | 36.123% |
| Amarin Corporation plc | -191.04 Million USD | 90.84% |
| Mesoblast Limited | 55.96 Million USD | 131.269% |
| Turnstone Biologics Corp. | -14.58 Million USD | -19.988% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 30.812% |
| Synaptogenix, Inc. | -28.66 Million USD | 38.946% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -1769.551% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 135.909% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -1929.837% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -140.831% |
| Exelixis, Inc. | -73.05 Million USD | 76.045% |
| Better Therapeutics, Inc. | -860 Thousand USD | -1934.767% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 27.127% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 92.75% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 2477.368% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -135.261% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 1495.455% |
| Gritstone bio, Inc. | 39.49 Million USD | 144.312% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 79.193% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -564.82% |
| Avid Bioservices, Inc. | 169.72 Million USD | 110.31% |
| Insmed Incorporated | 721.62 Million USD | 102.425% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -91.423% |
| MediWound Ltd. | -5.32 Million USD | -228.805% |
| OmniAb, Inc. | 9.2 Million USD | 290.145% |
| Alector, Inc. | -35.63 Million USD | 50.897% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 120.355% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -255.093% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 232.178% |
| Zai Lab Limited | -775 Million USD | 97.742% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 105.138% |
| Aura Biosciences, Inc. | -21.52 Million USD | 18.704% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 78.784% |
| Immunic, Inc. | -45.34 Million USD | 61.405% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 90.943% |
| Veracyte, Inc. | -203.82 Million USD | 91.415% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 102.742% |
| FibroGen, Inc. | 56.76 Million USD | 130.826% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 296.508% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -518.977% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -745.22% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.381% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -423.765% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 89.456% |
| TG Therapeutics, Inc. | 17.86 Million USD | 197.968% |
| Galecto, Inc. | -21.21 Million USD | 17.52% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 26.428% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 101.115% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 28.494% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -52.073% |
| XBiotech Inc. | -200.02 Million USD | 91.252% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 79.193% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 486.462% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 50.376% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 77.338% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 407.486% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 89.732% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 81.056% |
| Vaxxinity, Inc. | 10.13 Million USD | 272.71% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 102.377% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -62.516% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 73.469% |
| NexImmune, Inc. | -3.13 Million USD | -458.424% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -406.825% |
| Marker Therapeutics, Inc. | -15.11 Million USD | -15.8% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 35.428% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -94.952% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -13946.96% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 56.869% |
| Ainos, Inc. | 4.07 Million USD | 529.115% |
| Pluri Inc. | 22.82 Million USD | 176.653% |
| Prothena Corporation plc | -608.34 Million USD | 97.124% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 85.265% |
| Celularity Inc. | 65.19 Million USD | 126.843% |
| Rallybio Corporation | -24.1 Million USD | 27.396% |
| Cue Biopharma, Inc. | -33.81 Million USD | 48.257% |
| MeiraGTx Holdings plc | -40.3 Million USD | 56.58% |
| Omeros Corporation | 331.17 Million USD | 105.284% |
| Humacyte, Inc. | -22.48 Million USD | 22.178% |
| Immunocore Holdings plc | -358.59 Million USD | 95.12% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 28.793% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 43.371% |
| Blueprint Medicines Corporation | 702.83 Million USD | 102.49% |
| CalciMedica, Inc. | -5.53 Million USD | -216.438% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 90.703% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -71.324% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 56.293% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 47.376% |
| Pulmatrix, Inc. | -10.41 Million USD | -67.985% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -192.772% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 54.121% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 84.292% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 70.808% |
| Cytokinetics, Incorporated | 642.37 Million USD | 102.724% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -200.515% |
| Nutriband Inc. | -251.65 Thousand USD | -6853.512% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 48.712% |
| Vor Biopharma Inc. | 4.3 Million USD | 506.953% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.71% |
| Evogene Ltd. | -19.63 Million USD | 10.874% |
| ProKidney Corp. | -56.23 Million USD | 68.883% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 64.047% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -89.441% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 101.283% |
| CorMedix Inc. | -43.05 Million USD | 59.354% |
| BioLineRx Ltd. | 7.33 Million USD | 338.536% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 36.286% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 137.92% |
| Atai Life Sciences N.V. | -28.55 Million USD | 38.725% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 884.522% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 23.304% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 198.669% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 76.691% |
| MediciNova, Inc. | -50.78 Million USD | 65.542% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 77.795% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -77690.62% |
| GeoVax Labs, Inc. | -6.45 Million USD | -171.193% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 91.243% |
| Biomea Fusion, Inc. | -166.57 Million USD | 89.495% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 90.223% |
| Mereo BioPharma Group plc | -51.46 Million USD | 66.001% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 81.55% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 94.043% |
| Absci Corporation | -72.59 Million USD | 75.896% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 483.246% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 92.536% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 81.426% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 81.714% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 55.215% |
| Allakos Inc. | -24.97 Million USD | 29.934% |
| Imunon, Inc. | -4.21 Million USD | -315.273% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -18.702% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 87.076% |
| BioAtla, Inc. | -109.01 Million USD | 83.947% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 2477.368% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -1763.578% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 246.239% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 17.469% |
| XOMA Corporation | -29 Million USD | 39.659% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | -5.67% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -94.088% |
| aTyr Pharma, Inc. | -7.44 Million USD | -134.917% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 85.96% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 91.594% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 78.602% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 81.136% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -1936.7% |
| Akari Therapeutics, Plc | -3.84 Million USD | -355.111% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1178.262% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 101.267% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1372.812% |
| UroGen Pharma Ltd. | 4.39 Million USD | 498.52% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 115.42% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 24417.001% |
| Orgenesis Inc. | 21.78 Million USD | 180.33% |
| Entera Bio Ltd. | -10.62 Million USD | -64.634% |
| GH Research PLC | -78.07 Million USD | 77.588% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 21.487% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 34.36% |
| Xencor, Inc. | 29.64 Million USD | 159.03% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -788.359% |
| Replimune Group, Inc. | 1.41 Million USD | 1339.306% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -7045.132% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 86.158% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1372.812% |
| Portage Biotech Inc. | -4.98 Million USD | -251.315% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -77690.62% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 73.535% |
| OncoCyte Corporation | -6.56 Million USD | -166.631% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 2049.938% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -284.117% |
| Purple Biotech Ltd. | -14.13 Million USD | -23.773% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 26.339% |
| scPharmaceuticals Inc. | -6.54 Million USD | -167.364% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | -4.834% |
| HilleVax, Inc. | -165.48 Million USD | 89.426% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -589.48% |
| Tharimmune, Inc. | -10.93 Million USD | -60.022% |
| Genprex, Inc. | -6.73 Million USD | -159.72% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 95.255% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 80.218% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -1149.036% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -427.564% |
| OKYO Pharma Limited | -826.84 Thousand USD | -2016.35% |
| Savara Inc. | 153 Thousand USD | 11537.255% |
| Curis, Inc. | -23.88 Million USD | 26.743% |
| Daré Bioscience, Inc. | -5.15 Million USD | -239.265% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -2154.991% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -181.878% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 1576.709% |
| BeiGene, Ltd. | -2.25 Billion USD | 99.223% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 241.824% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 97.123% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 90.571% |
| Erasca, Inc. | -37.21 Million USD | 52.98% |
| bluebird bio, Inc. | 108.57 Million USD | 116.118% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1258.731% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 104.62% |
| DBV Technologies S.A. | -126.98 Million USD | 86.22% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1258.731% |
| Moderna, Inc. | -2.9 Billion USD | 99.398% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -69.04% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -61.014% |
| Molecular Templates, Inc. | 707 Thousand USD | 2575.106% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 44.219% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 105.049% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 78.676% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 80.923% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 45.777% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 49.095% |
| MacroGenics, Inc. | -66.98 Million USD | 73.876% |
| RenovoRx, Inc. | -1.17 Million USD | -1391.816% |
| Adicet Bio, Inc. | -138.78 Million USD | 87.391% |
| Prime Medicine, Inc. | -27.94 Million USD | 37.372% |
| Aditxt, Inc. | 18.12 Million USD | 196.568% |
| Adagene Inc. | -87.62 Million USD | 80.03% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -320.101% |
| Quantum-Si incorporated | -118.55 Million USD | 85.24% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 148.602% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -134.126% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 63.926% |
| SciSparc Ltd. | -2.06 Million USD | -747.409% |
| Vericel Corporation | 1.27 Million USD | 1470.321% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -45.926% |
| Minerva Neurosciences, Inc. | 41 Million USD | 142.676% |
| Generation Bio Co. | 31.44 Million USD | 155.644% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 90.021% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 43.411% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 115.009% |
| Invivyd, Inc. | -198.47 Million USD | 91.183% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 80.615% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -629.828% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 75.28% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -156.396% |
| 2seventy bio, Inc. | 181.71 Million USD | 109.63% |
| ADMA Biologics, Inc. | 90.06 Million USD | 119.429% |
| Clene Inc. | 3.34 Million USD | 623.922% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -92.663% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 18.651% |
| GeoVax Labs, Inc. | -6.45 Million USD | -171.193% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 94.915% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 32.695% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 109.849% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -327.685% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 449.84% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -235.938% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 86.571% |
| Evaxion Biotech A/S | 5.28 Million USD | 430.991% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 84.455% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 86.67% |
| Trevena, Inc. | 2.25 Million USD | 874.978% |
| Surrozen, Inc. | -32.66 Million USD | 46.427% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 66.028% |
| Cingulate Inc. | 3.08 Million USD | 667.655% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -495.812% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 343.481% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -88.339% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 77.94% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 86.688% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 83.42% |
| Clearmind Medicine Inc. | -3.94 Million USD | -343.84% |
| Kronos Bio, Inc. | -36.05 Million USD | 51.464% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 285.982% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1300.101% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 67.747% |
| Statera Biopharma, Inc. | 14.41 Million USD | 221.383% |
| ImmunityBio, Inc. | 618.22 Million USD | 102.831% |
| Korro Bio, Inc. | -132.94 Million USD | 86.837% |
| Kineta, Inc. | -4.54 Million USD | -285.356% |
| BioVie Inc. | -17.73 Million USD | 1.316% |
| Codexis, Inc. | -43.27 Million USD | 59.56% |
| Celularity Inc. | 65.19 Million USD | 126.843% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -452.193% |
| Celcuity Inc. | 6.78 Million USD | 357.964% |
| Virax Biolabs Group Limited | -3.36 Million USD | -420.038% |
| Cibus, Inc. | -8.07 Million USD | -116.625% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -313.786% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 482.91% |
| IN8bio, Inc. | -16.38 Million USD | -6.773% |
| Kodiak Sciences Inc. | -103.87 Million USD | 83.154% |
| Annexon, Inc. | -193.75 Million USD | 90.968% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 48708.333% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -398.121% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 101.66% |
| Eyenovia, Inc. | 1.25 Million USD | 1490.242% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 165.04% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -439.593% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 47.367% |
| Arcellx, Inc. | -296.95 Million USD | 94.107% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 10.289% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 70.278% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 15.574% |
| Moolec Science SA | 117.61 Thousand USD | 14978.078% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 54.429% |
| Geron Corporation | 14.76 Million USD | 218.549% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 53.85% |
| Royalty Pharma plc | 5.65 Billion USD | 100.309% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 87.626% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -150.364% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -226.3% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 87.566% |
| Humacyte, Inc. | -22.48 Million USD | 22.178% |
| Structure Therapeutics Inc. | -124.33 Million USD | 85.926% |
| 89bio, Inc. | -289.05 Million USD | 93.946% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 30.675% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -881.436% |
| Genelux Corporation | -6.89 Million USD | -153.645% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 43.659% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 120.932% |
| Notable Labs, Ltd. | -9.77 Million USD | -79.0% |
| Liquidia Corporation | -80.17 Million USD | 78.174% |
| Mustang Bio, Inc. | -3.73 Million USD | -368.389% |
| Immunovant, Inc. | -635.22 Million USD | 97.245% |
| Quantum-Si incorporated | -118.55 Million USD | 85.24% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 0.37% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -322.375% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 318.002% |
| Acasti Pharma Inc. | -23 Million USD | 23.934% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -419.685% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -7.69% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 87.296% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -461.52% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 21.289% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 5.762% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 89.663% |
| PepGen Inc. | -60.67 Million USD | 71.157% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 23.838% |
| United Therapeutics Corporation | -507.7 Million USD | 96.553% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 8.507% |
| Solid Biosciences Inc. | -47.75 Million USD | 63.353% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -1929.837% |
| Immuneering Corporation | -54.94 Million USD | 68.151% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -316.297% |
| Silo Pharma, Inc. | -3.52 Million USD | -396.523% |
| Belite Bio, Inc | -87.27 Million USD | 79.949% |
| XOMA Corporation | -29 Million USD | 39.659% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 75.248% |
| Bionomics Limited | 227 Million USD | 107.708% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 84.951% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -590.841% |
| uniQure N.V. | -102.95 Million USD | 83.003% |
| Cassava Sciences, Inc. | -121.13 Million USD | 85.554% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -320.101% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 142.732% |
| Forte Biosciences, Inc. | -11.96 Million USD | -46.3% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -465.542% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 16608.491% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -439.593% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 296.508% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -135.963% |
| Altimmune, Inc. | -134.48 Million USD | 86.988% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 108.835% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -590.841% |
| Compugen Ltd. | -12.9 Million USD | -35.609% |
| Peak Bio, Inc. | 10.34 Million USD | 269.233% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -6083.392% |
| Benitec Biopharma Inc. | -50.58 Million USD | 65.405% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 83.229% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 189.076% |
| Zura Bio Limited | -99.8 Million USD | 82.467% |
| PolyPid Ltd. | 6.17 Million USD | 383.614% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 123.609% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 189.076% |
| Instil Bio, Inc. | 75.35 Million USD | 123.221% |
| argenx SE | -2.02 Billion USD | 99.137% |
| Immunome, Inc. | -97.02 Million USD | 81.965% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 22.209% |
| Verona Pharma plc | -220.44 Million USD | 92.062% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 75.609% |
| Shattuck Labs, Inc. | -121.42 Million USD | 85.589% |
| CervoMed Inc. | -7.79 Million USD | -124.552% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 90.567% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -300.16% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 86.717% |
| Moolec Science SA | 117.61 Thousand USD | 14978.078% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -664.824% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 210.068% |
| AnaptysBio, Inc. | -18.15 Million USD | 3.592% |
| Design Therapeutics, Inc. | -18.15 Million USD | 3.587% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 75.137% |
| NeurAxis, Inc. | 145.7 Thousand USD | 12110.295% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 255.796% |
| Lumos Pharma, Inc. | -28.49 Million USD | 38.585% |
| Achilles Therapeutics plc | -126.92 Million USD | 86.213% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 75.609% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -2568.629% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 15.764% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1300.101% |
| Nutriband Inc. | -251.65 Thousand USD | -6853.512% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -32.86% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -135.202% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 105.144% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 173.727% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 96.089% |
| Palisade Bio, Inc. | -12.06 Million USD | -45.063% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 87.528% |
| Beam Therapeutics Inc. | -262.72 Million USD | 93.339% |
| Neurogene Inc. | -131.95 Million USD | 86.739% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 180.212% |
| AEON Biopharma, Inc. | -4.88 Million USD | -258.586% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 95.361% |
| Sesen Bio, Inc. | -112.55 Million USD | 84.453% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 82.476% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -645.338% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 55.161% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 78.988% |
| Athira Pharma, Inc. | -88.99 Million USD | 80.338% |
| Vaccinex, Inc. | -1.28 Million USD | -1258.618% |
| HCW Biologics Inc. | 2.85 Million USD | 712.565% |
| XOMA Corporation | -29 Million USD | 39.659% |
| Nektar Therapeutics | 210.24 Million USD | 108.323% |
| Arvinas, Inc. | -313.8 Million USD | 94.424% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1178.262% |
| Merus N.V. | -192.88 Million USD | 90.928% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 129.172% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -152.22% |
| Rezolute, Inc. | -68.16 Million USD | 74.33% |
| Clene Inc. | 3.34 Million USD | 623.922% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -32.699% |
| BeyondSpring Inc. | -13.75 Million USD | -27.219% |
| Synlogic, Inc. | -6.68 Million USD | -161.765% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 1643.122% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -106.966% |
| Peak Bio, Inc. | 10.34 Million USD | 269.233% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 78.769% |
| Krystal Biotech, Inc. | -350.23 Million USD | 95.004% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 114.098% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 89.645% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -454.267% |
| MannKind Corporation | 143.89 Million USD | 112.161% |
| Ikena Oncology, Inc. | -109.15 Million USD | 83.969% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -131.132% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 47.133% |
| Gossamer Bio, Inc. | 180.35 Million USD | 109.703% |
| CohBar, Inc. | -5.93 Million USD | -195.056% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 41.176% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 483.246% |
| Legend Biotech Corporation | -949.39 Million USD | 98.157% |
| Mural Oncology plc | -255.84 Million USD | 93.16% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 154.319% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -271.478% |
| Disc Medicine, Inc. | -358.28 Million USD | 95.116% |
| Champions Oncology, Inc. | 4.81 Million USD | 463.653% |
| REGENXBIO Inc. | 54.76 Million USD | 131.951% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -6407.454% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 88.413% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -94.174% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 78.311% |
| Vaxart, Inc. | -8.24 Million USD | -112.341% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 65.128% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 86.239% |
| Cellectis S.A. | -43.85 Million USD | 60.098% |
| Longeveron Inc. | -2.9 Million USD | -501.754% |
| Repare Therapeutics Inc. | -107.85 Million USD | 83.776% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 101.807% |
| Inozyme Pharma, Inc. | 12 Million USD | 245.776% |
| Revolution Medicines, Inc. | -608.2 Million USD | 97.123% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -1322.683% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 93.4% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 88.34% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | -11.836% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -2264.73% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.817% |
| Denali Therapeutics Inc. | -74.86 Million USD | 76.626% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -45.926% |
| Veru Inc. | 4.77 Million USD | 466.09% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -55.602% |
| Cingulate Inc. | 3.08 Million USD | 667.655% |
| Passage Bio, Inc. | 4.58 Million USD | 481.658% |
| Context Therapeutics Inc. | -14.44 Million USD | -21.102% |
| Exicure, Inc. | 5.84 Million USD | 399.179% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 92.404% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 55.777% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 211.523% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 70.25% |
| Nuvalent, Inc. | -335.38 Million USD | 94.782% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 1108.971% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 76.506% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -96.839% |
| OmniAb, Inc. | 9.2 Million USD | 290.145% |
| Anew Medical, Inc. | 1.43 Million USD | 1321.601% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 206.82% |
| Lipocine Inc. | -4.75 Million USD | -268.044% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 84.067% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 214.891% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 65.457% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 170.3% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -160.363% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 73.417% |
| Ocugen, Inc. | -32.52 Million USD | 46.192% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 79.551% |
| Q32 Bio Inc. | -37.94 Million USD | 53.887% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -2686.465% |
| Alumis Inc. Common Stock | -13.52 Million USD | -29.344% |
| Equillium, Inc. | -22.39 Million USD | 21.852% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 31.559% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 46.366% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -6958.468% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 113.055% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 647.186% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 5427.898% |
| Dominari Holdings Inc. | 195 Thousand USD | 9073.846% |
| Edesa Biotech, Inc. | -5.26 Million USD | -232.244% |
| vTv Therapeutics Inc. | -8.91 Million USD | -96.243% |
| Bio-Techne Corporation | 267.74 Million USD | 106.536% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | -7.959% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 85.182% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -108.247% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -38.321% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 92.861% |
| Nkarta, Inc. | 57.29 Million USD | 130.54% |
| BioCardia, Inc. | 212 Thousand USD | 8354.245% |
| Iterum Therapeutics plc | 13.43 Million USD | 230.22% |